Macromolecular HPMA-Based Nanoparticles with Cholesterol for Solid-Tumor Targeting: Detailed Study of the Inner Structure of a Highly Efficient Drug Delivery System

2012 ◽  
Vol 13 (8) ◽  
pp. 2594-2604 ◽  
Author(s):  
Sergey K. Filippov ◽  
Petr Chytil ◽  
Petr V. Konarev ◽  
Margarita Dyakonova ◽  
ChristineM. Papadakis ◽  
...  
2019 ◽  
Vol 7 (23) ◽  
pp. 3724-3736 ◽  
Author(s):  
Changliang Liu ◽  
Houqian Gao ◽  
Zijian Zhao ◽  
Iman Rostami ◽  
Chen Wang ◽  
...  

A dual-functional drug delivery system based on the conjugation of PAMAM dendrimer with EBP-1 and TAT peptide was established for the therapy of triple-negative breast cancer.


2019 ◽  
Vol 53 ◽  
pp. 101144 ◽  
Author(s):  
Simona Giarra ◽  
Noemi Lupo ◽  
Virginia Campani ◽  
Alfonso Carotenuto ◽  
Laura Mayol ◽  
...  

2019 ◽  
Vol 33 (10) ◽  
pp. 1394-1406 ◽  
Author(s):  
Juan Cai ◽  
Keyang Qian ◽  
Xueliang Zuo ◽  
Wuheng Yue ◽  
Yinzhu Bian ◽  
...  

Docetaxel (TXT) is acknowledged as one of the most important chemotherapy agents for gastric cancer (GC). PI3K/AKT signaling is frequently activated in GC, and its inhibitor LY294002 exerts potent antitumor effects. However, the hydrophobicity of TXT and the poor solubility and low bioavailability of LY294002 limit their clinical application. To overcome these shortcomings, we developed poly(lactic acid/glycolic) (PLGA) nanoparticles loaded with TXT and LY294002. PLGA facilitated the accumulation of TXT and LY294002 at the tumor sites. The in vitro functional results showed that PLGA(TXT+LY294002) exhibited controlled-release and resulted in a markedly reduced proliferative capacity and an elevated apoptosis rate. An in vivo orthotopic GC mouse model and xenograft mouse model confirmed the anticancer superiority and tumor-targeting feature of PLGA(TXT+LY294002). Histological analysis indicated that PLGA(TXT+LY294002) was biocompatible and had no toxicity to major organs. Characterized by the combined slow release of TXT and LY294002, this novel PLGA-based TXT/LY294002 drug delivery system provides controlled release and tumor targeting and is safe, shedding light on the future of targeted therapy against GC.


Nanoscale ◽  
2015 ◽  
Vol 7 (38) ◽  
pp. 16061-16070 ◽  
Author(s):  
Xiao-Gang Wang ◽  
Zhi-Yue Dong ◽  
Hong Cheng ◽  
Shuang-Shuang Wan ◽  
Wei-Hai Chen ◽  
...  

RSC Advances ◽  
2016 ◽  
Vol 6 (72) ◽  
pp. 68134-68140 ◽  
Author(s):  
Fang Ding ◽  
Fanhong Wu ◽  
Qingqing Tian ◽  
Lingling Guo ◽  
Jing Wang ◽  
...  

Graphene oxide has shown great potential in drug delivery.


Nanoscale ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 2966-2972 ◽  
Author(s):  
Zhao-Xia Chen ◽  
Miao-Deng Liu ◽  
Deng-Ke Guo ◽  
Mei-Zhen Zou ◽  
Shi-Bo Wang ◽  
...  

A tumor targeting drug delivery system was designed to interfere with lactate metabolism for tumor therapy and anti-metastasis research.


Molecules ◽  
2020 ◽  
Vol 25 (5) ◽  
pp. 1088 ◽  
Author(s):  
Jlenia Brunetti ◽  
Sara Piantini ◽  
Marco Fragai ◽  
Silvia Scali ◽  
Giulia Cipriani ◽  
...  

The development of selective tumor targeting agents to deliver multiple units of chemotherapy drugs to cancer tissue would improve treatment efficacy and greatly advance progress in cancer therapy. Here we report a new drug delivery system based on a tetrabranched peptide known as NT4, which is a promising cancer theranostic by virtue of its high cancer selectivity. We developed NT4 directly conjugated with one, two, or three units of paclitaxel and an NT4-based nanosystem, using NIR-emitting quantum dots, loaded with the NT4 tumor-targeting agent and conjugated with paclitaxel, to obtain a NT4-QD-PTX nanodevice designed to simultaneously detect and kill tumor cells. The selective binding and in vitro cytotoxicity of NT4-QD-PTX were higher than for unlabeled QD-PTX when tested on the human colon adenocarcinoma cell line HT-29. NT4-QD-PTX tumor-targeted nanoparticles can be considered promising for early tumor detection and for the development of effective treatments combining simultaneous therapy and diagnosis.


2020 ◽  
Vol 2020 ◽  
pp. 1-13
Author(s):  
Yi-Zhi Zhu ◽  
Di Xu ◽  
Zhen Liu ◽  
Tian Tian ◽  
Fei Deng ◽  
...  

Triple-negative breast cancer (TNBC) is a highly malignant tumor. At present, there are still no targeted drugs for TNBC. Clinical chemotherapeutic drugs, such as doxorubicin (DOX), have the characteristic of nontargeted distribution in treatment of TNBC, causing severe side effects. Therefore, new target treatment strategies for TNBC are of urgent need. It was speculated that glutamine could be a potential target because it is in high demand by TNBC. In this study, we found that the transporter for glutamine, ASCT2 (solute carrier family 1 member 5 (SLC1A5)), is highly expressed in TNBC by analysis of data from The Cancer Genome Atlas (TCGA) and experiments in vitro. Based on this, glutamine was grafted onto a polymeric drug carrier in order to develop a tumor-targeting drug delivery system for treatment of TNBC. Firstly, pH-responsive glutamine-PEG5000-b-PAE10000 (Gln-PEG-b-PAE) copolymers were synthesized using Fmoc-PEG5000-b-PAE10000 (Fmoc-PEG-b-PAE) copolymers. Then, Gln-PEG-b-PAE@DOX micelles were prepared by loading DOX to Gln-PEG-b-PAE copolymer using a solvent casting technology. In vitro, Gln-PEG-b-PAE@DOX micelles exhibited pH-dependent micellization-decellularization behavior; namely, they can rapidly release DOX in acidic environment of pH 6.0 but release very slowly in physiological condition. Moreover, glutamine competition experiment showed that Gln-PEG-b-PAE@DOX micelles had the ability to target MDA-MB-231 cells. Compared to free DOX, Gln-PEG-b-PAE@DOX micelles had significantly greater cytotoxic effect and antiproliferative activity against MDA-MB-231 cells. In vivo, compared to free DOX and mPEG-b-PAE@DOX micelles, Gln-PEG-b-PAE@DOX micelles significantly inhibited tumor growth in tumor-bearing mice. Therefore, Gln-PEG-b-PAE@DOX micelles, as a tumor-targeting drug delivery system, may provide a new method for the treatment of TNBC.


Sign in / Sign up

Export Citation Format

Share Document